byiShook Opinion
Sep 26, 2024 - 13:00
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. The post Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. appeared first on Investor's Business Daily.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
The post Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. appeared first on Investor's Business Daily.